The Food and Drug Administration yesterday updated two guidances for the temporary compounding of certain drugs used to treat COVID-19 patients.

The guidance for temporary compounding of certain drugs for outsourcing facilities now includes information to help hospitals determine which facilities are covered by the policy, and clarifies policies for testing both container-closures and product stability. It also says FDA will not take action against outsourcing facilities for filling drug orders for copies of FDA-approved products.

In addition, FDA updated guidance for temporary compounding of certain drugs by pharmacy compounders to include reporting to FDA any adverse events associated with drugs they compounded. 

Related News Articles

Headline
President Biden today announced new actions to spur more vaccinations nationwide against COVID-19, due in part to the rise of the SARS-CoV-2 delta variant.…
Headline
The AHA today released new Spanish-language public service announcements and related content pieces to support vaccination efforts and complement previously…
Headline
AHA today urged the Centers for Medicare & Medicaid Services to make permanent COVID-19 waivers that removed regulatory barriers to better patient care,…
Headline
The Food and Drug Administration July 28 extended to six months the shelf life for Johnson & Johnson’s COVID-19 vaccine. The decision is based on data from…
Headline
The Provider Relief Fund Deadline Extension Act (S. 2493/H.R. 4735) was introduced yesterday in the Senate and House. The AHA-supported bill would allow…
Headline
The AHA yesterday joined the U.S. Chamber of Commerce and American Medical Association in urging the 11th Circuit Court of Appeals to void a district court…